Eptinezumab clinical trials
Also written Vyepti and ALD403.
How each study uses eptinezumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the eptinezumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 21 Feb 2020 · VYEPTI · BLA 761119 (FDA, Drugs@FDA)
- European Union
- 24 Jan 2022 · Vyepti · EMEA/H/C/005287 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
27 studies that test it; most in 2021 (7)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 7 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 23 · Other 4
H. Lundbeck A/S (16) · Alder Biopharmaceuticals, Inc. (6) · Dr George Medvedev (1) · Stanford University (1) · Rigmor Højland Jensen (1) · Sunnybrook Health Sciences Centre (1) · Mayo Clinic (1)
Often tested with
Tested in the same studies.
Galcanezumab (2) · Erenumab (2) · Atogepant (1) · Onabotulinum toxin A (1) · Botulinum toxin type A (1) · Fremanezumab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 3 in phase 3
Studies that test eptinezumab, phase 3 first.
- Mar 2027A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic MigrainePhase 3 · H. Lundbeck A/S
- Jun 2027Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)Phase 3 · Sunnybrook Health Sciences Centre
- Jul 2027A Study of Eptinezumab in Pediatric Participants With Episodic MigrainePhase 3 · H. Lundbeck A/S
Studies
Open first, then newest update. How each study uses eptinezumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 27
- Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)RecruitingPhase 3Sunnybrook Health Sciences CentreNCT07191145Written as Eptinezumab
- A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic MigraineRecruitingPhase 3H. Lundbeck A/SNCT04965675Written as Eptinezumab
- A Study of Eptinezumab in Pediatric Participants With Episodic MigraineRecruitingPhase 3H. Lundbeck A/SNCT05897320Written as Eptinezumab
- A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic MigraineRecruitingPhase 3H. Lundbeck A/SNCT05164172Written as Eptinezumab
- Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency ContextEnrolling by invitationPhase 3Dr George MedvedevNCT06428838Written as Eptinezumab
- Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)Not yet recruitingPhase 4Stanford UniversityNCT07655440Written as Eptinezumab
- Eptinezumab for Chronic Headache in Idiopathic Intracranial HypertensionNot yet recruitingPhase 3Rigmor Højland JensenNCT07645833Written as Eptinezumab
- A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP MedicationsCompletedPhase 4H. Lundbeck A/SNCT06701526Written as Eptinezumab
- A Study of Eptinezumab in Participants With Migraine and Medication Overuse HeadacheCompletedPhase 4H. Lundbeck A/SNCT05452239Written as Eptinezumab
- Eptinezumab as Preventive Treatment of Migraine in Adults With MigraineCompletedPhase 3H. Lundbeck A/SNCT04921384Written as Eptinezumab
- Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in JapanCompletedPhase 3H. Lundbeck A/SNCT05064371Written as Eptinezumab
- A Study of CGRP Monoclonal Antibody to Treat Diabetic NeuropathyWithdrawnPhase 2Mayo ClinicNCT05937152Written as Eptinezumab
- Eptinezumab in Participants With Episodic Cluster HeadacheCompletedPhase 3H. Lundbeck A/SNCT04688775Written as Eptinezumab
- A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)CompletedPhase 3H. Lundbeck A/SNCT05064397Written as Eptinezumab
- Real World Effectiveness of Eptinezumab in Participants With MigraineTerminatedPhase 4H. Lundbeck A/SNCT05284019Written as Eptinezumab
- A Study in Children and Young People With Migraine to Learn What the Body Does to EptinezumabCompletedPhase 1H. Lundbeck A/SNCT04537429Written as Eptinezumab
- A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive TreatmentsCompletedPhase 3H. Lundbeck A/SNCT04418765Written as Eptinezumab
- Eptinezumab in Adults With Migraine and Medication Overuse HeadacheCompletedPhase 3H. Lundbeck A/SNCT04772742Written as Eptinezumab
- Safety, Tolerability and Pharmacokinetics of Eptinezumab in Healthy Chinese SubjectsCompletedPhase 1H. Lundbeck A/SNCT05045781Written as Eptinezumab
- A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of MigraineCompletedPhase 3H. Lundbeck A/SNCT04152083Written as Eptinezumab
See all 27 studies that test eptinezumab →
Given beside what is tested · 1 — eptinezumab is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)Oct 29, 2026NCT07191145
Codes
What other systems call eptinezumab · ClinicalTrials.gg INT000985
- MeSH (NLM) C000628361eptinezumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 8202AY8I7HEPTINEZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2282660One source FDA
- Wikidata Q28208949eptinezumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171835EptinezumabOne source FDA
- DrugBank DB14040One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000628361 | eptinezumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 8202AY8I7H | EPTINEZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2282660 | — | One source FDA |
| Wikidata | Q28208949 | eptinezumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171835 | Eptinezumab | One source FDA |
| DrugBank | DB14040 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.